Optimal duration of adjuvant chemotherapy for high-risk node-negative (N–) breast cancer patients: 6-year results of the prospective randomised multicentre phase III UNICANCER-PACS 05 trial (UCBG-0106)

Auteurs

Pierre Kerbrat, Isabelle Desmoulins, Lise Roca, Christelle Levy, Alain Lortholary, Alain Marre, Rémy Delva, Maria Rios, Patrice Viens, Étienne Brain, Daniel Serin, Magali Edel, Marc Debled, Mario Campone, Marie-Ange Mourret-Reynier, Thomas Bachelot, Marie-Josèphe Foucher-Goudier, Bernard Asselain, Jérôme Lemonnier, Anne-Laure Martin, Henri Roché